{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:36:48Z","timestamp":1789583808825,"version":"build-2803163510"},"reference-count":135,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01-BX002348"],"award-info":[{"award-number":["I01-BX002348"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-DK081646"],"award-info":[{"award-number":["R01-DK081646"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21-AG082416"],"award-info":[{"award-number":["R21-AG082416"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1053\/j.ajkd.2025.10.017","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:15:17Z","timestamp":1768868117000},"page":"716-729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Navigating Anemia Therapy in CKD With Hypoxia-Inducible Factor Activators: A Review"],"prefix":"10.1053","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-8994","authenticated-orcid":false,"given":"Volker H.","family":"Haase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiesda A.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Koury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1053\/j.ajkd.2025.10.017_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.017_bib2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.exphem.2005.06.031","article-title":"Erythropoietin: the story of hypoxia and a finely regulated hematopoietic hormone","volume":"33","author":"Koury","year":"2005","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib3","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib4","first-page":"283","article-title":"KDIGO 2012 Clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Summary of recommendation statements","volume":"2","year":"2012","journal-title":"Kidney Int Suppl."},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib5","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int Suppl (2011)"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.kint.2023.05.009","article-title":"Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"104","author":"Ku","year":"2023","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib7","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol Cell"},{"key":"10.1053\/j.ajkd.2025.10.017_bib8","series-title":"FibroGen reports third quarter 2024 financial results","year":"2024"},{"key":"10.1053\/j.ajkd.2025.10.017_bib9","article-title":"Jesduvroq (daprodustat) tablets, for oral use. Prescribing information","year":"2023","journal-title":"GlaxoSmithKline"},{"key":"10.1053\/j.ajkd.2025.10.017_bib10","series-title":"Vafseo (vadadustat) tablets, for oral use. Prescribing information","year":"2024"},{"key":"10.1053\/j.ajkd.2025.10.017_bib11","article-title":"FDA briefing document: Cardiovascular and Renal Drugs Advisory Committee meeting, July 15, 2021: roxadustat","year":"2021","journal-title":"US Food and Drug Administration"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrneph.2013.21","article-title":"Anaemia management and mortality risk in chronic kidney disease","volume":"9","author":"Horl","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"87","key":"10.1053\/j.ajkd.2025.10.017_bib13","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1046\/j.1523-1755.64.s87.6.x","article-title":"Anemia as a risk factor for cardiovascular disease","author":"Pereira","year":"2003","journal-title":"Kidney Int Suppl"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2025.10.017_bib15","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.ajkd.2025.10.017_bib16","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1053\/j.ajkd.2025.10.017_bib17","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2025.10.017_bib19","first-page":"ii1","article-title":"Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","article-title":"2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease","volume":"3","author":"Yamamoto","year":"2017","journal-title":"Ren Replace Ther"},{"issue":"1S","key":"10.1053\/j.ajkd.2025.10.017_bib22","first-page":"S1","article-title":"KDIGO 2026 Clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","year":"2026","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.ajkd.2012.07.014","article-title":"Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis","volume":"61","author":"Koulouridis","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib24","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","article-title":"Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis","volume":"13","author":"Evans","year":"2020","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib25","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2215\/CJN.02380607","article-title":"Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets","volume":"2","author":"Fishbane","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-inducible factor activators in renal anemia: current clinical experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.017_bib27","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1681\/ASN.2022040413","article-title":"Hypoxia-inducible factor-prolyl hydroxyl domain inhibitors: from theoretical superiority to clinical noninferiority compared with current ESAs?","volume":"33","author":"Locatelli","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s004240050084","article-title":"Divergent regulation of vascular endothelial growth factor and of erythropoietin gene expression in vivo","volume":"431","author":"Sandner","year":"1996","journal-title":"Pflugers Arch"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","article-title":"Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects","volume":"30","author":"Hara","year":"2015","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","article-title":"A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis","volume":"20","author":"Bailey","year":"2019","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.34067\/KID.0000092020","article-title":"Mannose binding lectin is hydroxylated by collagen prolyl-4-hydroxylase and inhibited by some PHD inhibitors","volume":"1","author":"Bhute","year":"2020","journal-title":"Kidney360"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib32","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.kint.2017.03.008","article-title":"Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor","volume":"92","author":"Kiriakidis","year":"2017","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.017_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nrneph.2015.193","article-title":"HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond","volume":"12","author":"Maxwell","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40780-024-00351-z","article-title":"Association between roxadustat use and suppression of thyroid function: a systematic review and meta-analysis","volume":"10","author":"Nakano","year":"2024","journal-title":"J Pharm Health Care Sci"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib35","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1172\/JCI30117","article-title":"Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo","volume":"117","author":"Rankin","year":"2007","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1053\/j.ajkd.2025.10.017_bib36","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1182\/blood-2010-02-270322","article-title":"Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia","volume":"116","author":"Kapitsinou","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.ajkd.2025.10.017_bib37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1056\/NEJM199105093241907","article-title":"Erythropoietin","volume":"324","author":"Erslev","year":"1991","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.017_bib38","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1681\/ASN.2015050508","article-title":"Increased synthesis of liver erythropoietin with CKD","volume":"27","author":"De Seigneux","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.10.017_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jpba.2013.04.009","article-title":"Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis","volume":"81-82","author":"Lonnberg","year":"2013","journal-title":"J Pharm Biomed Anal"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.017_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.017_bib41","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13826","article-title":"EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis","volume":"235","author":"Kobayashi","year":"2022","journal-title":"Acta Physiol (Oxf)"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib43","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease","volume":"26","author":"Bhandari","year":"2025","journal-title":"BMC Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib44","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1053\/j.ajkd.2021.09.017","article-title":"Recent and emerging therapies for iron deficiency in anemia of CKD: a review","volume":"79","author":"Bazeley","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2025.10.017_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-med-043021-032816","article-title":"Hepcidin and iron in health and disease","volume":"74","author":"Nemeth","year":"2023","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.017_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41580-023-00648-1","article-title":"Mechanisms controlling cellular and systemic iron homeostasis","volume":"25","author":"Galy","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib47","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2007-04-087593","article-title":"Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2\/4","volume":"110","author":"Lin","year":"2007","journal-title":"Blood"},{"issue":"17","key":"10.1053\/j.ajkd.2025.10.017_bib48","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2018893099","article-title":"Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis","volume":"134","author":"Parrow","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib49","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ajh.26644","article-title":"Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease","volume":"97","author":"Koury","year":"2022","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e15310","article-title":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: a systematic review and meta-analysis","volume":"9","author":"Zheng","year":"2023","journal-title":"Heliyon"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib51","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/ckj\/sfad080","article-title":"Effect of roxadustat on red blood cell lifespan in patients with long-term haemodialysis: a single-centre, prospective, single-arm study","volume":"16","author":"Zhao","year":"2023","journal-title":"Clin Kidney J"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.017_bib52","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1634\/stemcells.2008-0369","article-title":"Constitutive expression of HIF-1\u03b1 and HIF-2\u03b1 in bone marrow stromal cells differentially promotes their proangiogenic properties","volume":"26","author":"Ben-Shoshan","year":"2008","journal-title":"Stem Cells"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib53","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1182\/blood-2007-11-122648","article-title":"The microenvironment for erythropoiesis is regulated by HIF-2\u03b1 through VCAM-1 in endothelial cells","volume":"112","author":"Yamashita","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.017_bib54","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9440(10)64554-3","article-title":"The expression and distribution of the hypoxia-inducible factors HIF-1\u03b1 and HIF-2\u03b1 in normal human tissues, cancers, and tumor-associated macrophages","volume":"157","author":"Talks","year":"2000","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.017_bib55","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/ndt\/gfl716","article-title":"Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients","volume":"22","author":"Rossert","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2025.10.017_bib56","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12882-015-0138-x","article-title":"Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients","volume":"16","author":"Sibbel","year":"2015","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib57","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","article-title":"Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients","volume":"68","author":"Luo","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12882-019-1554-0","article-title":"In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study","volume":"20","author":"Ingrasciotta","year":"2019","journal-title":"BMC Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.017_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277921","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: the BRIGHTEN Study","volume":"17","author":"Narita","year":"2022","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib60","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000523947","article-title":"Resistance to erythropoiesis-stimulating agents among patients on hemodialysis is typically transient","volume":"53","author":"Goodkin","year":"2022","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.017_bib61","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.017_bib62","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1093\/ndt\/gfq802","article-title":"Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID Study","volume":"26","author":"Panichi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.017_bib63","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1093\/ndt\/gfs007","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients","volume":"27","author":"Minutolo","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.017_bib64","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000358215","article-title":"Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients","volume":"37","author":"Okazaki","year":"2014","journal-title":"Blood Purif"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2020.06.008","article-title":"Clinical and economic outcomes of erythropoiesis-stimulating agent hyporesponsiveness in the post-bundling era","volume":"2","author":"Cizman","year":"2020","journal-title":"Kidney Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib66","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/pds.3755","article-title":"Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study","volume":"24","author":"Gillespie","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kisu.2020.12.006","article-title":"Treatment of anemia in difficult-to-manage patients with chronic kidney disease","volume":"11","author":"Raichoudhury","year":"2021","journal-title":"Kidney Int Suppl (2011)"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.017_bib68","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS Study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib69","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2215\/CJN.00550122","article-title":"Three times weekly dosing of daprodustat versus conventional epoetin for treatment of anemia in hemodialysis patients: ASCEND-TD: a phase 3 randomized, double-blind, noninferiority trial","volume":"17","author":"Coyne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2025.10.017_bib70","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib71","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/hdi.70034","article-title":"Safety and efficacy of vadadustat versus darbepoetin alfa for chronic kidney disease-related anemia in patients receiving dialysis by baseline erythropoiesis-stimulating agent dose","volume":"30","author":"Jardine","year":"2026","journal-title":"Hemodial Int"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.017_bib72","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s11739-021-02738-4","article-title":"Roxadustat for dialysis patients with erythropoietin hypo-responsiveness: a single-center, prospective investigation","volume":"16","author":"Zhou","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib73","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.017_bib74","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1681\/ASN.0000000708","article-title":"Safety and efficacy of vadadustat for the treatment of CKD-related anemia within and outside the United States","volume":"36","author":"Chertow","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2025.10.017_bib75","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.017_bib76","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association","volume":"39","author":"Stoumpos","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.017_bib77","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology (Carlton)"},{"issue":"17","key":"10.1053\/j.ajkd.2025.10.017_bib78","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib79","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/cdd.2008.21","article-title":"The role of hypoxia-inducible factors in tumorigenesis","volume":"15","author":"Rankin","year":"2008","journal-title":"Cell Death Differ"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.017_bib80","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.017_bib81","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1172\/JCI120855","article-title":"Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers","volume":"129","author":"Chappell","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ajkd.2025.10.017_bib82","series-title":"Welireg (belzutifan) tablets, for oral use. Prescribing information","year":"2021"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3324\/haematol.2011.044644","article-title":"Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia","volume":"97","author":"Ladroue","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib84","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1038\/s41467-018-05554-1","article-title":"HIF-2\u03b1-pVHL complex reveals broad genotype-phenotype correlations in HIF-2\u03b1-driven disease","volume":"9","author":"Tarade","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.017_bib85","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-2006-939441","article-title":"Vascular complications in Chuvash polycythemia","volume":"32","author":"Gordeuk","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.ajkd.2025.10.017_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/HP.S130526","article-title":"Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer","volume":"5","author":"Seeley","year":"2017","journal-title":"Hypoxia (Auckl)"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib87","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/1091581817737232","article-title":"Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats","volume":"36","author":"Beck","year":"2017","journal-title":"Int J Toxicol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.017_bib88","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0192623319880445","article-title":"Carcinogenicity assessment of daprodustat (GSK1278863), a hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor","volume":"48","author":"Adams","year":"2020","journal-title":"Toxicol Pathol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib89","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.10.017_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109524","article-title":"Role of oxygen and the HIF-pathway in polycystic kidney disease","volume":"69","author":"Buchholz","year":"2020","journal-title":"Cell Signal"},{"key":"10.1053\/j.ajkd.2025.10.017_bib91","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cophys.2018.12.003","article-title":"Revisiting the role of hypoxia-inducible factors in pulmonary hypertension","volume":"7","author":"Shimoda","year":"2019","journal-title":"Curr Opin Physiol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib92","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib93","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s00125-011-2081-0","article-title":"Ischaemia-induced retinal neovascularisation and diabetic retinopathy in mice with conditional knockout of hypoxia-inducible factor-1 in retinal Muller cells","volume":"54","author":"Lin","year":"2011","journal-title":"Diabetologia"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib94","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12882-019-1244-y","article-title":"Post renal transplant anemia: severity, causes and their association with graft and patient survival","volume":"20","author":"Schechter","year":"2019","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib95","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1034\/j.1600-6143.2002.20506.x","article-title":"Late post-transplant anemia in adult renal transplant recipients. An under-recognized problem?","volume":"2","author":"Yorgin","year":"2002","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.017_bib96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0609.1997.tb00943.x","article-title":"Assessment of erythropoiesis following renal transplantation","volume":"58","author":"Beshara","year":"1997","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib97","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1432-2277.2008.00814.x","article-title":"Iron deficiency anemia and iron losses after renal transplantation","volume":"22","author":"Zheng","year":"2009","journal-title":"Transpl Int"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.017_bib98","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1432-2277.2012.01513.x","article-title":"Anemia and erythrocytosis in patients after kidney transplantation","volume":"25","author":"Malyszko","year":"2012","journal-title":"Transpl Int"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib99","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1016\/j.transproceed.2014.10.035","article-title":"Parameters influencing blood erythropoietin levels of renal transplant recipients during the early post-transplantation period","volume":"46","author":"Kalantzi","year":"2014","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/oxfordjournals.ndt.a027037","article-title":"Erythropoietin deficiency and relative resistance cause anaemia in post-renal transplant recipients with normal renal function","volume":"11","author":"Nampoory","year":"1996","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib101","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ki.1987.241","article-title":"Dynamics of erythropoiesis following renal transplantation","volume":"32","author":"Besarab","year":"1987","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.017_bib102","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4103\/UA.UA_89_19","article-title":"Epidemiology of parvovirus B19 and anemia among kidney transplant recipients: a meta-analysis","volume":"12","author":"Thongprayoon","year":"2020","journal-title":"Urol Ann"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib103","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10157-009-0170-x","article-title":"Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients","volume":"13","author":"Kawada","year":"2009","journal-title":"Clin Exp Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib104","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/ajt.13795","article-title":"Impact of early blood transfusion after kidney transplantation on the incidence of donor-specific anti-HLA antibodies","volume":"16","author":"Ferrandiz","year":"2016","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.017_bib105","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1681\/ASN.2006010027","article-title":"Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality","volume":"17","author":"Imoagene-Oyedeji","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.017_bib106","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1046\/j.1600-6143.2004.00604.x","article-title":"Percentage of hypochromic red blood cells is an independent risk factor for mortality in kidney transplant recipients","volume":"4","author":"Winkelmayer","year":"2004","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.017_bib107","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1093\/ndt\/gfl457","article-title":"A prospective study of anaemia and long-term outcomes in kidney transplant recipients","volume":"21","author":"Winkelmayer","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib108","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ekir.2024.04.021","article-title":"The efficacy and safety of roxadustat for the treatment of posttransplantation anemia: a randomized study","volume":"9","author":"Kong","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.017_bib109","doi-asserted-by":"crossref","first-page":"11859","DOI":"10.21037\/apm-21-2916","article-title":"Efficacy and safety of roxadustat in the treatment of renal allograft anemia patients: a case series","volume":"10","author":"Li","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000535071","article-title":"Roxadustat for patients with posttransplant anemia: a narrative review","volume":"10","author":"Tang","year":"2024","journal-title":"Kidney Dis (Basel)"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.017_bib111","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.transproceed.2024.01.016","article-title":"Daprodustat for post-transplant anemia in renal transplant recipients","volume":"56","author":"Machida","year":"2024","journal-title":"Transplant Proc"},{"issue":"50","key":"10.1053\/j.ajkd.2025.10.017_bib112","doi-asserted-by":"crossref","first-page":"21276","DOI":"10.1073\/pnas.0903978106","article-title":"Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model","volume":"106","author":"Bernhardt","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib113","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1681\/ASN.2006070792","article-title":"Immunohistochemical detection of hypoxia-inducible factor-1\u03b1 in human renal allograft biopsies","volume":"18","author":"Rosenberger","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib114","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.transproceed.2016.10.017","article-title":"Hypoxia-inducible factor-1\u03b1 expression in kidney transplant biopsy specimens after reperfusion is associated with early recovery of graft function after cadaveric kidney transplantation","volume":"49","author":"Oda","year":"2017","journal-title":"Transplant Proc"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib115","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.017_bib116","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.017_bib117","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib118","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"17","key":"10.1053\/j.ajkd.2025.10.017_bib119","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in patients with anemia and non-dialysis-dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.017_bib120","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib121","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.017_bib122","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv Ther"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib123","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES Study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib124","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2\u03b1, but not HIF-1\u03b1, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.017_bib125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell Metab"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.017_bib126","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2\u03b1 mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"issue":"34","key":"10.1053\/j.ajkd.2025.10.017_bib127","doi-asserted-by":"crossref","first-page":"24142","DOI":"10.1074\/jbc.274.34.24142","article-title":"Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation","volume":"274","author":"Tacchini","year":"1999","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib128","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jcp.1041500109","article-title":"Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon","volume":"150","author":"Means","year":"1992","journal-title":"J Cell Physiol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.017_bib129","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1172\/JCI116216","article-title":"Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon","volume":"91","author":"Means","year":"1993","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib130","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2010-10-315218","article-title":"Chronic IFN-gamma production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1\/PU.1 axis","volume":"118","author":"Libregts","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.017_bib131","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200164","article-title":"IL-33 promotes anemia during chronic inflammation by inhibiting differentiation of erythroid progenitors","volume":"217","author":"Swann","year":"2020","journal-title":"J Exp Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.017_bib132","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41590-021-00895-4","article-title":"Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias","volume":"22","author":"Raundhal","year":"2021","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.017_bib133","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1089\/jir.1998.18.555","article-title":"Proinflammatory cytokines lowering erythropoietin production","volume":"18","author":"Jelkmann","year":"1998","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.017_bib134","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.cmet.2009.03.006","article-title":"A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression","volume":"9","author":"Zhang","year":"2009","journal-title":"Cell Metab"},{"issue":"19","key":"10.1053\/j.ajkd.2025.10.017_bib135","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1056\/NEJMcibr0906391","article-title":"The microcytic red cell and the anemia of inflammation","volume":"361","author":"Keel","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.017_bib136","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1751-553X.2011.01355.x","article-title":"Low hemoglobin density potential marker of iron availability","volume":"34","author":"Urrechaga","year":"2012","journal-title":"Int J Lab Hematol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626000089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626000089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:55:56Z","timestamp":1778086556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626000089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":135,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0272638626000089"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.10.017","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating Anemia Therapy in CKD With Hypoxia-Inducible Factor Activators: A Review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}